Abeona Therapeutics Inc.
ABEO
$4.60
$0.5313.02%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | 250.00% | -- | -97.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | 250.00% | -- | -97.73% |
| Cost of Revenue | 15.54% | 113.29% | 44.09% | -23.75% | -97.69% |
| Gross Profit | -50.00% | -113.29% | -9.82% | 21.16% | 97.67% |
| SG&A Expenses | 2.60% | 6.84% | 45.12% | -5.37% | 29.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.58% | 20.83% | 44.43% | -18.49% | -29.86% |
| Operating Income | -10.20% | -20.83% | -22.72% | 16.54% | 15.51% |
| Income Before Tax | -132.99% | -83.96% | -306.49% | 58.69% | 84.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -132.99% | -83.96% | -306.49% | 58.69% | 84.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -132.99% | -83.96% | -306.49% | 58.69% | 84.75% |
| EBIT | -10.20% | -20.83% | -22.72% | 16.54% | 15.51% |
| EBITDA | -12.98% | -25.73% | -26.56% | 16.42% | 15.86% |
| EPS Basic | -21.65% | 52.37% | 31.88% | 85.84% | 95.24% |
| Normalized Basic EPS | -43.20% | 52.36% | -2.76% | 80.34% | 86.76% |
| EPS Diluted | -21.65% | 52.37% | 31.88% | 85.84% | 95.24% |
| Normalized Diluted EPS | -43.20% | 52.36% | -2.76% | 80.34% | 86.76% |
| Average Basic Shares Outstanding | 91.51% | 286.18% | 210.31% | 191.69% | 220.35% |
| Average Diluted Shares Outstanding | 91.51% | 286.18% | 210.31% | 191.69% | 220.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
